Immunovant annual meeting: directors elected, E&Y ratified, say-on-pay approved

Immunovant, Inc.

198,373,370 shares represented (~96% of eligible) at Sept 2, 2026 annual meeting.
Directors Bauer, Hughes, Susman elected with 162.9M, 174.1M, 181.6M votes for, respectively.
Ernst & Young ratified as independent auditor for FY ending March 31, 2027 (198.1M for).
Non-binding say-on-pay approved: 180.8M for, 8.4M against, 91.9K abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.